PMID- 20703257
OWN - NLM
STAT- MEDLINE
DCOM- 20101112
LR  - 20130304
IS  - 1476-5551 (Electronic)
IS  - 0887-6924 (Linking)
VI  - 24
IP  - 10
DP  - 2010 Oct
TI  - The impact of HLA matching on long-term transplant outcome after allogeneic 
      hematopoietic stem cell transplantation for CLL: a retrospective study from the 
      EBMT registry.
PG  - 1725-31
LID - 10.1038/leu.2010.165 [doi]
AB  - We analyzed 368 chronic lymphocytic leukemia patients who underwent allogeneic 
      hematopoietic stem cell transplantation reported to the EBMT registry between 
      1995 and 2007. There were 198 human leukocyte antigen (HLA)-identical siblings; 
      among unrelated transplants, 31 were well matched in high resolution ('well 
      matched' unrelated donor, WMUD), and 139 were mismatched (MM), including 30 
      matched in low resolution; 266 patients (72%) received reduced-intensity 
      conditioning and 102 (28%) received standard. According to the EBMT risk score, 
      11% were in scores 1-3, 23% in score 4, 40% in score 5, 22% in score 6 and 4% in 
      score 7. There was no difference in overall survival (OS) at 5 years between 
      HLA-identical siblings (55% (48-64)) and WMUD (59% (41-84)), P=0.82. In contrast, 
      OS was significantly worse for MM (37% (29-48) P=0.005) due to a significant 
      excess of transplant-related mortality. Also OS worsened significantly when EBMT 
      risk score increased. HLA matching had no significant impact on relapse 
      (siblings: 24% (21-27); WMUD: 35% (26-44), P=0.11 and MM: 21% (18-24), P=0.81); 
      alemtuzumab T-cell depletion and stem cell source (peripheral blood) were 
      associated with an increased risk. Our findings support the use of WMUD as 
      equivalent alternative to HLA-matched sibling donors for allogeneic HSCT in CLL, 
      and justify the application of EBMT risk score in this disease.
FAU - Michallet, M
AU  - Michallet M
AD  - Department of Hematology, Edouard Herriot Hospital, Lyon, France. 
      mauricette.michallet@chu-lyon.fr
FAU - Sobh, M
AU  - Sobh M
FAU - Milligan, D
AU  - Milligan D
FAU - Morisset, S
AU  - Morisset S
FAU - Niederwieser, D
AU  - Niederwieser D
FAU - Koza, V
AU  - Koza V
FAU - Ruutu, T
AU  - Ruutu T
FAU - Russell, N H
AU  - Russell NH
FAU - Verdonck, L
AU  - Verdonck L
FAU - Dhedin, N
AU  - Dhedin N
FAU - Vitek, A
AU  - Vitek A
FAU - Boogaerts, M
AU  - Boogaerts M
FAU - Vindelov, L
AU  - Vindelov L
FAU - Finke, J
AU  - Finke J
FAU - Dubois, V
AU  - Dubois V
FAU - van Biezen, A
AU  - van Biezen A
FAU - Brand, R
AU  - Brand R
FAU - de Witte, T
AU  - de Witte T
FAU - Dreger, P
AU  - Dreger P
CN  - Chronic Leukemia Working Party of the EBMT
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
DEP - 20100812
PL  - England
TA  - Leukemia
JT  - Leukemia
JID - 8704895
RN  - 0 (HLA Antigens)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Female
MH  - Follow-Up Studies
MH  - Graft vs Host Disease/etiology/*prevention & control
MH  - HLA Antigens/*metabolism
MH  - *Hematopoietic Stem Cell Transplantation
MH  - Histocompatibility Testing
MH  - Humans
MH  - Leukemia, Myelogenous, Chronic, BCR-ABL Positive/immunology/*metabolism/*therapy
MH  - Male
MH  - Middle Aged
MH  - Registries
MH  - Retrospective Studies
MH  - Siblings
MH  - Survival Rate
MH  - Transplantation, Homologous
MH  - Treatment Outcome
FIR - Willemze, R
IR  - Willemze R
FIR - Nagler, A
IR  - Nagler A
FIR - Ljungman, P
IR  - Ljungman P
FIR - Remes, K
IR  - Remes K
FIR - Greinix, H
IR  - Greinix H
FIR - Ganser, A
IR  - Ganser A
FIR - Beguin, Y
IR  - Beguin Y
FIR - Kroger, N
IR  - Kroger N
FIR - Buzyn, A
IR  - Buzyn A
FIR - Lenhoff, S
IR  - Lenhoff S
FIR - Schwerdtfeger, R
IR  - Schwerdtfeger R
FIR - Hunter, A E
IR  - Hunter AE
FIR - Dreger, P
IR  - Dreger P
FIR - Sanz, M
IR  - Sanz M
FIR - Franklin, I
IR  - Franklin I
FIR - Robinson, S
IR  - Robinson S
FIR - Sayer, H G
IR  - Sayer HG
FIR - Hallek, M
IR  - Hallek M
FIR - Yin, Liu J
IR  - Yin LJ
FIR - Littlewood, T
IR  - Littlewood T
FIR - Cook, G
IR  - Cook G
FIR - Malek, H
IR  - Malek H
FIR - Nousiainen, T
IR  - Nousiainen T
FIR - Uharek, L
IR  - Uharek L
FIR - Theunissen, K
IR  - Theunissen K
EDAT- 2010/08/13 06:00
MHDA- 2010/11/13 06:00
CRDT- 2010/08/13 06:00
PHST- 2010/08/13 06:00 [entrez]
PHST- 2010/08/13 06:00 [pubmed]
PHST- 2010/11/13 06:00 [medline]
AID - leu2010165 [pii]
AID - 10.1038/leu.2010.165 [doi]
PST - ppublish
SO  - Leukemia. 2010 Oct;24(10):1725-31. doi: 10.1038/leu.2010.165. Epub 2010 Aug 12.